Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor. As a result of concerns for potential infusion-related hypersensitivity reactions (HSRs), initial phase ...
– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...
Usefulness of frailty markers in the assessment of the health and functional status in older cancer patient referred for chemotherapy No significant financial relationships to disclose. This is an ...
She made her doctor repeat it several times: There's nothing there. There's nothing there. There's no evidence of cancer. Last May, after four years of battling breast cancer -- cancer that infested ...
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
We’re delighted that NICE has approved bevacizumab for first- and second-line treatment in combination with chemotherapy for advanced bowel cancer patients in England and Wales, following a similar ...
To determine the dose-limiting toxicity (DLT), maximum tolerated dose, recommended dose (RD) and preliminary evidence of activity of escalating doses of irinotecan (CPT-11) fixed-dose-rate infusional ...
Until last week, there were no treatments approved to keep ovarian cancer away in women who'd responded to an initial round of chemo but didn’t have a BRCA mutation. Now there are two. AstraZeneca and ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the completion of a supplemental Biologics License Application (sBLA) ...
Background Localized rectal cancer responds well to 5-fluorouracil and radiation-based regimens. A phase I–II trial is currently testing the efficacy of adding bevacizumab, a VEGF-specific antibody, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback